pdf
Published
2022-11-16
Issue
Section
Community Engagement
Categories
License
Copyright (c) 2022 Alexandria Boot, Crystal Deas
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright of content published in INNOVATIONS in pharmacy belongs to the author(s).
What’s Trending on Twitter Regarding the Most Recently Approved Oral Agent for HIV Pre-Exposure Prophylaxis (PrEP)?
Alexandria Boot
Ascension Sacred Heart, Pensacola, FL
Crystal Deas
Samford University, McWhorter School of Pharmacy
DOI: https://doi.org/10.24926/iip.v13i4.4794
Keywords: HIV prevention, social media, content analysis, pre-exposure prophylaxis, Descovy
Abstract
Introduction: Pre-exposure prophylaxis (PrEP) is a key therapeutic strategy for HIV prevention. Descovy® is the most recently approved oral agent for PrEP. Despite availability, there continues to be suboptimal PrEP use among at-risk individuals. Social media platforms have a role in disseminating health information, to include education on PrEP.
Material and methods: A content analysis was conducted of “tweets” posted on Twitter® during the initial year of Descovy’s FDA approval for PrEP. The coding schema captured content related to the indication, appropriate use, costs, and safety profile of Descovy.
Results: Most tweets provided information on target population, dosing strategy, and side effects of Descovy. Information on costs and appropriate use was frequently missing.
Conclusion: Health educators and providers should be aware of gaps in social media messaging concerning PrEP and should educate patients to ensure they are well informed when considering PrEP.
